Abstract
Alzheimers disease (AD) is characterized by the presence, in the brain of the patients, of two aberrant structures: intracellular neurofibrillary tangles (NFTs), containing an abnormal hyperphosphorylated form of tau protein, and extracellular senile plaques (SPs), mainly composed by fibrillar amyloid β peptide. Another feature of AD is the neurodegeneration and dysfunction of basal forebrain cholinergic system. A possible connection among those AD characteristics could occur. Thus, the purpose of this short review is to summarize the involvement of nicotinic (nAChR) and muscarinic (mAChR) receptors on tau phosphorylation, in a direct way, or through the previous interaction of some of these receptors with amyloid β. Several studies have demonstrated that nAChR activation results in a significantly increase of tau phosphorylation, whereas mAChR activation, may prevent tau phosphorylation.
Keywords: Alzheimer's disease, tau phosphorylation, amyloid b peptide, nicotinic receptors, muscarinic receptors, acetylcholine
Current Molecular Medicine
Title: Acetylcholine Receptors and Tau Phosphorylation
Volume: 6 Issue: 4
Author(s): A. Rubio, M. Pérez and Jesus Ávila
Affiliation:
Keywords: Alzheimer's disease, tau phosphorylation, amyloid b peptide, nicotinic receptors, muscarinic receptors, acetylcholine
Abstract: Alzheimers disease (AD) is characterized by the presence, in the brain of the patients, of two aberrant structures: intracellular neurofibrillary tangles (NFTs), containing an abnormal hyperphosphorylated form of tau protein, and extracellular senile plaques (SPs), mainly composed by fibrillar amyloid β peptide. Another feature of AD is the neurodegeneration and dysfunction of basal forebrain cholinergic system. A possible connection among those AD characteristics could occur. Thus, the purpose of this short review is to summarize the involvement of nicotinic (nAChR) and muscarinic (mAChR) receptors on tau phosphorylation, in a direct way, or through the previous interaction of some of these receptors with amyloid β. Several studies have demonstrated that nAChR activation results in a significantly increase of tau phosphorylation, whereas mAChR activation, may prevent tau phosphorylation.
Export Options
About this article
Cite this article as:
Rubio A., Pérez M. and Ávila Jesus, Acetylcholine Receptors and Tau Phosphorylation, Current Molecular Medicine 2006; 6 (4) . https://dx.doi.org/10.2174/156652406777435444
DOI https://dx.doi.org/10.2174/156652406777435444 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine Editorial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology Compartmentalized Platforms for Neuro-Pharmacological Research
Current Neuropharmacology Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Neurotrophin Propeptides: Biological Functions and Molecular Mechanisms
Current Protein & Peptide Science Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides
Current HIV Research LHON: Mitochondrial Mutations and More
Current Genomics Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry Immunotoxins and Other Conjugates: Pre-clinical Studies
Mini-Reviews in Medicinal Chemistry Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine The Action of Prostaglandins on Ion Channels
Current Neuropharmacology Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections
Current Medicinal Chemistry Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets